;PMID: 1931483
;source_file_2967.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..30] = [t:0..30]
;1)sentence:[e:36..126] = [t:36..126]
;2)section:[e:130..159] = [t:130..159]
;3)section:[e:163..252] = [t:163..252]
;4)sentence:[e:256..446] = [t:256..446]
;5)sentence:[e:447..583] = [t:447..583]
;6)sentence:[e:584..768] = [t:584..768]
;7)sentence:[e:769..825] = [t:769..825]
;8)sentence:[e:826..1108] = [t:826..1108]
;9)sentence:[e:1110..1174] = [t:1110..1174]
;10)sentence:[e:1175..1260] = [t:1175..1260]
;11)sentence:[e:1261..1414] = [t:1261..1414]
;12)sentence:[e:1415..1483] = [t:1415..1483]
;13)section:[e:1487..1531] = [t:1487..1531]

;section 0 Span:0..30
;Cell Signal.  1991;3(4):333-9.
(SEC
  (FRAG (NNP:[0..4] Cell) (NNP:[5..11] Signal) (.:[11..12] .)
        (CD:[14..21] 1991;3-LRB-) (NN:[21..22] 4) (-RRB-:[22..23] -RRB-)
        (::[23..24] :) (CD:[24..27] 333) (::[27..28] -) (CD:[28..30] 9.)))

;sentence 1 Span:36..126
;A quantitative analysis of the role of K+ channels in mitogenesis of 
;neuroblastoma cells.
;[75..86]:gene-protein:"K+ channels"
;[106..119]:malignancy-type:"neuroblastoma"
(SENT
  (NP-HLN
    (NP (DT:[36..37] A) (JJ:[38..50] quantitative) (NN:[51..59] analysis))
    (PP (IN:[60..62] of)
      (NP
        (NP (DT:[63..66] the) (NN:[67..71] role))
        (PP (IN:[72..74] of)
          (NP (NN:[75..77] K+) (NNS:[78..86] channels)))
        (PP (IN:[87..89] in)
          (NP
            (NP (NN:[90..101] mitogenesis))
            (PP (IN:[102..104] of)
              (NP (NN:[106..119] neuroblastoma) (NNS:[120..125] cells)))))))
    (.:[125..126] .)))

;section 2 Span:130..159
;Rouzaire-Dubois B, Dubois JM.
(SEC
  (FRAG (NNP:[130..138] Rouzaire) (HYPH:[138..139] -) (NNP:[139..145] Dubois)
        (NNP:[146..147] B) (,:[147..148] ,) (NNP:[149..155] Dubois)
        (NNP:[156..158] JM) (.:[158..159] .)))

;section 3 Span:163..252
;Laboratoire de Physiologie Comparee, URA CNRS 1121, Universite Paris-Sud,
;Orsay,  France.
(SEC
  (FRAG (NNP:[163..174] Laboratoire) (IN:[175..177] de)
        (NNP:[178..189] Physiologie) (NNP:[190..198] Comparee) (,:[198..199] ,)
        (NNP:[200..203] URA) (NNP:[204..208] CNRS) (CD:[209..213] 1121)
        (,:[213..214] ,) (NNP:[215..225] Universite) (NNP:[226..235] Paris-Sud)
        (,:[235..236] ,) (NNP:[237..242] Orsay) (,:[242..243] ,)
        (NNP:[245..251] France) (.:[251..252] .)))

;sentence 4 Span:256..446
;The role of K+ channels in mitogenesis was studied on mouse neuroblastoma
;cells  by analysing the effects of various chemical agents on the whole-cell
;K+ current  and the cell proliferation.
;[268..279]:gene-protein:"K+ channels"
;[316..329]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[256..259] The) (NN:[260..264] role))
      (PP (IN:[265..267] of)
        (NP (NN:[268..270] K+) (NNS:[271..279] channels)))
      (PP (IN:[280..282] in)
        (NP (NN:[283..294] mitogenesis))))
    (VP (VBD:[295..298] was)
      (VP (VBN:[299..306] studied)
        (NP-1 (-NONE-:[306..306] *))
        (PP (IN:[307..309] on)
          (NP (NN:[310..315] mouse) (NN:[316..329] neuroblastoma)
              (NNS:[330..335] cells)))
        (PP-MNR (IN:[337..339] by)
          (S-NOM
            (NP-SBJ (-NONE-:[339..339] *))
            (VP (VBG:[340..349] analysing)
              (NP
                (NP (DT:[350..353] the) (NNS:[354..361] effects))
                (PP (IN:[362..364] of)
                  (NP (JJ:[365..372] various) (JJ:[373..381] chemical)
                      (NNS:[382..388] agents)))
                (PP (IN:[389..391] on)
                  (NP
                    (NP (DT:[392..395] the)
                      (NML (JJ:[396..401] whole) (HYPH:[401..402] -)
                           (NN:[402..406] cell))
                      (NN:[407..409] K+) (NN:[410..417] current))
                    (CC:[419..422] and)
                    (NP (DT:[423..426] the) (NN:[427..431] cell)
                        (NN:[432..445] proliferation))))))))))
    (.:[445..446] .)))

;sentence 5 Span:447..583
;The outward current recorded during depolarizations  on undifferentiated
;cells was made up of a small and slow inactivating K+  current.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[447..450] The) (JJ:[451..458] outward) (NN:[459..466] current))
      (VP (VBN:[467..475] recorded)
        (NP (-NONE-:[475..475] *))
        (PP-TMP (IN:[476..482] during)
          (NP
            (NP (NNS:[483..498] depolarizations))
            (PP (IN:[500..502] on)
              (NP (JJ:[503..519] undifferentiated) (NNS:[520..525] cells)))))))
    (VP (VBD:[526..529] was)
      (VP (VBN:[530..534] made)
        (NP-1 (-NONE-:[534..534] *))
        (PRT (RP:[535..537] up))
        (PP-CLR (IN:[538..540] of)
          (NP (DT:[541..542] a)
            (ADJP (JJ:[543..548] small) (CC:[549..552] and) (JJ:[553..557] slow))
            (VBG:[558..570] inactivating) (NN:[571..573] K+)
             (NN:[575..582] current)))))
    (.:[582..583] .)))

;sentence 6 Span:584..768
;Foetal calf serum, which is mitogen for neuroblastoma cells, shifted in 
;opposite directions by 7-10 mV peak activation and steady-state 
;inactivation-voltage curves of the K+ current.
;[624..637]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ
      (NP
        (NML (JJ:[584..590] Foetal) (NN:[591..595] calf))
        (NN:[596..601] serum))
      (,:[601..602] ,)
      (SBAR
        (WHNP-1 (WDT:[603..608] which))
        (S
          (NP-SBJ-1 (-NONE-:[608..608] *T*))
          (VP (VBZ:[609..611] is)
            (NP-PRD (NN:[612..619] mitogen))
            (PP (IN:[620..623] for)
              (NP (NN:[624..637] neuroblastoma) (NNS:[638..643] cells)))))))
    (,:[643..644] ,)
    (VP (VBD:[645..652] shifted)
      (PP (IN:[653..655] in)
        (NP (JJ:[657..665] opposite) (NNS:[666..676] directions)))
      (PP (IN:[677..679] by)
        (NP
          (NP
            (QP (CD:[680..681] 7) (HYPH:[681..682] -) (CD:[682..684] 10))
            (NN:[685..687] mV)
            (NML
              (NML
                (NML (JJ:[688..692] peak) (NN:[693..703] activation))
                (CC:[704..707] and)
                (NML
                  (NML (JJ:[708..714] steady) (HYPH:[714..715] -)
                       (NN:[715..720] state))
                  (NN:[722..734] inactivation)))
              (HYPH:[734..735] -)
              (NML (NN:[735..742] voltage) (NNS:[743..749] curves))))
          (PP (IN:[750..752] of)
            (NP (DT:[753..756] the) (NN:[757..759] K+) (NN:[760..767] current))))))
    (.:[767..768] .)))

;sentence 7 Span:769..825
;The resulting effect was an  increase in K+ conductance.
(SENT
  (S
    (NP-SBJ (DT:[769..772] The) (VBG:[773..782] resulting)
            (NN:[783..789] effect))
    (VP (VBD:[790..793] was)
      (NP-PRD
        (NP (DT:[794..796] an) (NN:[798..806] increase))
        (PP (IN:[807..809] in)
          (NP (NN:[810..812] K+) (NN:[813..824] conductance)))))
    (.:[824..825] .)))

;sentence 8 Span:826..1108
;The effect on the resting K+ flux of the classical  K+ channel blockers
;tetraethylammonium, 4-aminopyridine and capsaicin, the  anticancer agent
;tamoxifen, the heat inactivated serum and the increase in  external K+
;concentration were estimated from their effects on the K+ current.
;[878..888]:gene-protein:"K+ channel"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[826..829] The) (NN:[830..836] effect))
      (PP (IN:[837..839] on)
        (NP
          (NP (DT:[840..843] the) (VBG:[844..851] resting) (NN:[852..854] K+)
              (NN:[855..859] flux))
          (PP (IN:[860..862] of)
            (NP
              (NP
                (NP (DT:[863..866] the) (JJ:[867..876] classical)
                  (NML (NN:[878..880] K+) (NN:[881..888] channel))
                  (NNS:[889..897] blockers))
                (NP (NN:[898..916] tetraethylammonium) (,:[916..917] ,)
                    (NN:[918..933] 4-aminopyridine) (CC:[934..937] and)
                    (NN:[938..947] capsaicin)))
              (,:[947..948] ,)
              (NP
                (NP (DT:[949..952] the) (JJ:[954..964] anticancer)
                    (NN:[965..970] agent))
                (NN:[971..980] tamoxifen))
              (,:[980..981] ,)
              (NP (DT:[982..985] the)
                (ADJP (NN:[986..990] heat) (VBN:[991..1002] inactivated))
                (NN:[1003..1008] serum))
              (CC:[1009..1012] and)
              (NP
                (NP (DT:[1013..1016] the) (NN:[1017..1025] increase))
                (PP (IN:[1026..1028] in)
                  (NP (JJ:[1030..1038] external) (SYM:[1039..1041] K+)
                      (NN:[1042..1055] concentration)))))))))
    (VP (VBD:[1056..1060] were)
      (VP (VBN:[1061..1070] estimated)
        (NP-1 (-NONE-:[1070..1070] *))
        (PP (IN:[1071..1075] from)
          (NP
            (NP (PRP$:[1076..1081] their) (NNS:[1082..1089] effects))
            (PP (IN:[1090..1092] on)
              (NP (DT:[1093..1096] the) (NN:[1097..1099] K+)
                  (NN:[1100..1107] current)))))))
    (.:[1107..1108] .)))

;sentence 9 Span:1110..1174
;The cell proliferation was determined under the same conditions.
(SENT
  (S
    (NP-SBJ-1 (DT:[1110..1113] The) (NN:[1114..1118] cell)
              (NN:[1119..1132] proliferation))
    (VP (VBD:[1133..1136] was)
      (VP (VBN:[1137..1147] determined)
        (NP-1 (-NONE-:[1147..1147] *))
        (PP (IN:[1148..1153] under)
          (NP (DT:[1154..1157] the) (JJ:[1158..1162] same)
              (NNS:[1163..1173] conditions)))))
    (.:[1173..1174] .)))

;sentence 10 Span:1175..1260
;The results  indicate that cell proliferation is correlated to the resulting
;K+ flux.
(SENT
  (S
    (NP-SBJ (DT:[1175..1178] The) (NNS:[1179..1186] results))
    (VP (VBP:[1188..1196] indicate)
      (SBAR (IN:[1197..1201] that)
        (S
          (NP-SBJ-1 (NN:[1202..1206] cell) (NN:[1207..1220] proliferation))
          (VP (VBZ:[1221..1223] is)
            (VP (VBN:[1224..1234] correlated)
              (NP-1 (-NONE-:[1234..1234] *))
              (PP (TO:[1235..1237] to)
                (NP (DT:[1238..1241] the) (VBG:[1242..1251] resulting)
                    (SYM:[1252..1254] K+) (NN:[1255..1259] flux))))))))
    (.:[1259..1260] .)))

;sentence 11 Span:1261..1414
;It is  supposed that mitogenesis is controlled by the intracellular Na+
;concentration  which, via a cell volume regulation, is a function of the K+
;flux.
(SENT
  (S
    (NP-SBJ-3
      (NP (PRP:[1261..1263] It))
      (SBAR-4 (-NONE-:[1263..1263] *EXP*)))
    (VP (VBZ:[1264..1266] is)
      (VP (VBN:[1268..1276] supposed)
        (NP-3 (-NONE-:[1276..1276] *))
        (SBAR-4 (IN:[1277..1281] that)
          (S
            (NP-SBJ-2 (NN:[1282..1293] mitogenesis))
            (VP (VBZ:[1294..1296] is)
              (VP (VBN:[1297..1307] controlled)
                (NP-2 (-NONE-:[1307..1307] *))
                (PP (IN:[1308..1310] by)
                  (NP-LGS
                    (NP (DT:[1311..1314] the) (JJ:[1315..1328] intracellular)
                        (NN:[1329..1332] Na+) (NN:[1333..1346] concentration))
                    (SBAR
                      (WHNP-1 (WDT:[1348..1353] which))
                      (,:[1353..1354] ,)
                      (S
                        (NP-SBJ-1 (-NONE-:[1354..1354] *))
                        (PP (IN:[1355..1358] via)
                          (NP (DT:[1359..1360] a)
                            (NML (NN:[1361..1365] cell) (NN:[1366..1372] volume))
                            (NN:[1373..1383] regulation)))
                        (,:[1383..1384] ,)
                        (VP (VBZ:[1385..1387] is)
                          (NP-PRD
                            (NP (DT:[1388..1389] a) (NN:[1390..1398] function))
                            (PP (IN:[1399..1401] of)
                              (NP (DT:[1402..1405] the) (NN:[1406..1408] K+)
                                  (NN:[1409..1413] flux)))))))))))))))
    (.:[1413..1414] .)))

;sentence 12 Span:1415..1483
;A  quantitative model is developed on the basis of these hypotheses.
(SENT
  (S
    (NP-SBJ-1 (DT:[1415..1416] A) (JJ:[1418..1430] quantitative)
              (NN:[1431..1436] model))
    (VP (VBZ:[1437..1439] is)
      (VP (VBN:[1440..1449] developed)
        (NP-1 (-NONE-:[1449..1449] *))
        (PP (IN:[1450..1452] on)
          (NP
            (NP (DT:[1453..1456] the) (NN:[1457..1462] basis))
            (PP (IN:[1463..1465] of)
              (NP (DT:[1466..1471] these) (NNS:[1472..1482] hypotheses)))))))
    (.:[1482..1483] .)))

;section 13 Span:1487..1531
;PMID: 1931483 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1487..1491] PMID) (::[1491..1492] :) (CD:[1493..1500] 1931483)
        (NN:[1501..1502] -LSB-) (NNP:[1502..1508] PubMed) (::[1509..1510] -)
        (NN:[1511..1518] indexed) (IN:[1519..1522] for)
        (NNP:[1523..1531] MEDLINE-RSB-)))
